Journal of Clinical Oncology
Articles in this Issue
A prospective single-arm study of irinotecan liposome II combined with adebrelimab, gemcitabine, and nab-paclitaxel for conversion therapy in locally advanced pancreatic cancer.
TPS4265 Background: Locally advanced pancreatic cancer (LAPC) has an extremely poor prognosis, with only a minority of pat...
Radiomics feature robustness of photon-counting CT and DECT in chest tumor phantom: A dual-center, multi-device study.
e20011 Background: Robustness of radiomics features across CT platforms is essential for clinical translation of quantitat...
Neoadjuvant chemoradiotherapy with or without PD-1 blockade in pMMR/MSS low rectal cancer patients (CHOICE II): A multi-center, open-label, randomized controlled trial.
3640 Background: Neoadjuvant chemoradiotherapy (nCRT) combined with PD-1 blockade has shown great potential for improving...
Real-world usability of a clinical trial knowledge platform in a community cancer network.
e13712 Background: Clinical trial participation in the United States remains suboptimal, and limited point-of-care trial a...
Factors affecting outcomes in early-onset vs average-onset head and neck cancers: A multicenter retrospective database study.
e18108 Background: The incidence of early-onset (EO) head and neck squamous cell carcinoma (HNSCC) is increasing and appea...
Prognostic potential of PROSTest for predicting outcome in ADT-treated Black South African prostate cancer patients.
5104 Background: Prostate cancer (PCa) is the second most common cancer in men with disproportionately aggressive disease...
Validation of SNHG11 as a prognostic and predictive biomarker for anti-EGFR benefit in colorectal cancer using real-world data.
3138 Background: Long non-coding RNAs (lncRNAs) regulate colorectal cancer (CRC) initiation, progression, and therapeutic...
Predicting neoadjuvant chemoradiotherapy response and postoperative recurrence in locally advanced rectal cancer using a preoperative large language model.
3614 Background: Neoadjuvant chemoradiotherapy (nCRT) is standard for locally advanced rectal cancer (LARC), yet responses...
Toxicity and efficacy characterization of doxorubicin and trabectedin association versus doxorubicin alone in patients over 70 years with leiomyosarcoma: Analysis from LMS02 and LMS04 studies.
11515 Background: LMS02 (phase II) and LMS04 (randomized phase III) trials demonstrated the superiority of a combination r...
Prognosis and management of DCIS with/without microinvasion: Retrospective analysis from SEER and CSCO databases.
e12615 Background: The prognosis and management of patients with ductal carcinoma in situ (DCIS) with microinvasion (DCISM...
Role expansion of advanced practice providers over 5 years at Hawai'i's NCI Community Oncology Research Program.
9041 Background: Advanced Practice Providers (APPs), including Nurse Practitioners and Physician Associates, are key membe...
Axi-cel vs. tisa-cel vs. liso-cel in R/R DLBCL: Meta-analysis of the efficacy-safety trade-off.
e22002 Background: CD19-directed chimeric antigen receptor T-cell (CAR-T) therapies have improved outcomes for patients wi...
Hepatic arterial infusion chemotherapy plus either toripalimab or sorafenib as first-line therapy for non–high-risk, locally advanced hepatocellular carcinoma: A non-comparative, randomized phase 2 trial.
4115 Background: A combination of locoregional therapy such as hepatic arterial infusion chemotherapy (HAIC) with anti-ang...
First-line real-world outcomes of atezolizumab- and pembrolizumab-based regimens in non-squamous non–small-cell lung cancer.
e20591 Background: Direct prospective comparisons of first-line treatment options for advanced non-squamous non–small-cell...
Real-world effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients aged ≥65 years with metastatic triple-negative breast cancer.
1124 Background: Patients aged ≥65 years constitute a substantial proportion of individuals with metastatic triple-negativ...
Neurological immune-related adverse events and overall survival in patients with advanced solid tumors treated with immune checkpoint inhibitors in a global real-world analysis.
11165 Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced malignancies, and many im...
Targeting the delta opioid receptor (DOR) on myeloid immunosuppressive cells: Novel therapeutic approach to hematological malignancies.
e14566 Background: Despite recent progress in the treatment options for hematological malignancies, there remains signific...
A randomized phase II trial of folate receptor alpha peptide vaccine in early-stage triple-negative breast cancer.
536 Background: Folate receptor alpha (FRα) is overexpressed in ~80% of triple-negative breast cancers (TNBC). We previous...
Cell-free DNA nucleosome and genomic signatures as predictors of outcomes with radium-223 in metastatic castration-resistant prostate cancer.
5039 Background: Radium-223 (Ra-223) is a bone-seeking alpha emitter that induces double-stranded DNA breaks. Previous stu...
Association of survival benefit with treatment at academic cancer programs in older adults with PTCL: A National Cancer Database analysis.
e19075 Background: Peripheral T cell lymphoma (PTCL) is an aggressive mature T cell neoplasm associated with poor prognosi...
Trends in breast cancer incidence, mortality, and disability-adjusted life years in Europe, 1990-2023: A region- and sex-specific analysis.
e12721 Background: Breast cancer is a major contributor to the cancer burden in Europe, with marked regional and sex-speci...
Utilization trends in CAR T cell therapy and bispecific antibodies among Medicare beneficiaries: A five-year claims analysis (2019-2023).
e19012 Background: T-cell engaging therapies, including chimeric antigen receptor T-cell (CAR T-cell) therapy and many bis...
Integrative spatial omics to identify determinants of response to neoadjuvant chemo-immunotherapy in triple-negative breast cancer.
e12650 Background: Triple-negative breast cancer (TNBC) demonstrates heterogeneous response to neoadjuvant chemotherapy. P...
Dexamethasone-free antiemetic prophylaxis with olanzapine in children and adolescents receiving highly emetogenic chemotherapy: A multicenter, phase III non-inferiority randomized trial.
10017 Background: Dexamethasone, with a 5-HT3 receptor antagonist and a neurokinin-1 antagonist, is the guideline-recommen...
Comprehensive clinicogenomic profiling of mucinous carcinomas of the gastrointestinal tract.
e15205 Background: Mucinous carcinoma (MC) is a rare, aggressive histological subtype of adenocarcinoma that is associated...